Open AccessGenome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2
Author(s) -
Garam Kım,
Lisa Nakayama,
Jacob A. Blum,
Tetsuya Akiyama,
Steven Boeynaems,
Meenakshi Chakraborty,
Julien Couthouis,
Eduardo Tassoni-Tsuchida,
Caitlin M. Rodriguez,
Michael C. Bassik,
Aaron D. Gitler
Publication year - 2022
Publication title -
cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.264
H-Index - 154
eISSN - 2639-1856
pISSN - 2211-1247
DOI - 10.1016/j.celrep.2022.111508
Subject(s) - spinocerebellar ataxia , biology , druggability , gene , amyotrophic lateral sclerosis , crispr , atpase , microbiology and biotechnology , drug discovery , genetics , computational biology , biochemistry , disease , enzyme , medicine , pathology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom